Using data from registries across Europe and Canada, Aymon et al. compared the incidence of major adverse cardiac events (MACE) in patients with RA treated with JAK inhibitors, TNF inhibitors or biologic DMARDs with other modes of action over two years. The researchers did not find an increased risk of MACE with JAK inhibitors over that time frame.
Dr. Diane van der Woude reviewed provided a detailed review of the latest research on rheumatoid arthritis, addressing findings on disease prevention, supplements, novel treatments and much more.
This report presents a rare case of bilateral pulmonary artery stenosis secondary to granulomatosis with polyangiitis, underscoring the importance of recognizing large-vessel involvement as a potential manifestation of AAV; it also includes a narrative review analyzing eight previously reported cases.
As measles outbreaks increase domestically & internationally, while vaccination uptake decreases in the U.S., experts discuss treatment recommendations & the immunologic consequences of measles infections in patients with rheumatic diseases.
Experts provided an in-depth review of Janus kinase (JAK) inhibitors, discussing the latest research on their use in the treatment of specific rheumatic conditions, the risks associated with them and more.
In a session at EULAR 2025, Dr. Laura Coates discussed the management of PsA, providing insights into the current research and when clinicians may want to consider prescribing specific medications.
Experts discussed how aspects of the immune system other than B cells play a role in lupus, including mitochondria in red blood cells, proteins present in urine and more.
An overview of highlights from the 2025 ECIM meeting, including research on treatment options for systemic sclerosis, the management of PMR & autoimmune testing.